

factor and competent to express the protein or factor when implanted in the mammal.

107. (New) The method of claim 106 wherein the transfected cell becomes attached to the wall of the vessel in the mammal.

108. (New) The method of claim 106 wherein the transfected cell is an endothelial cell or a smooth muscle cell.

109. (New) The method of claim 106 wherein the exogenous nucleic acid encodes a therapeutic agent.

sub E⁴ 110. (New) The method of claim 106 wherein the recombinant protein or factor is competent to induce angiogenesis.

111. (New) The method of claim 106 wherein the recombinant protein or factor is competent to induce revascularization.

D¹ 112. (New) The method of claim 106 wherein the protein or factor is useful in the treatment of an ischemic organ.

113. (New) The method of claim 112 wherein the organ is a heart, liver, bowel, kidney or brain.

sub E⁵ 114. (New) The method of claim 106 wherein the protein or factor is competent to improve the vascular or cerebrovascular circulation.

115. (New) A method of treating a human patient comprising the step of site-specific instillation of cells into the patient, wherein the cells are selected from the group consisting of endothelium, smooth muscle, fibroblasts, monocytes, macrophages, and parenchymal cells.

116. (New) The method of claim 115, wherein the cells produce protein in the patient.

117. (New) The method of claim 116, wherein the protein is secreted by the cells.

118. (New) The method of claim 116, wherein the protein has a therapeutic effect.

119. (New) The method of claim 118, wherein the protein is an angiogenic factor.

Sub F-3 120. ~~(New) The method of claim 116, wherein the protein has a diagnostic effect.~~

121. (New) The method of claim 115, wherein the cells are genetically altered *in vitro* prior to being instilled to the patient.

122. (New) The method of claim 115, wherein the cells are instilled into a body vessel within the patient.

123. (New) The method of claim 122, wherein the vessel is a blood vessel.

124. (New) The method of claim 122, wherein the cells are instilled intravenously.

125. (New) The method of claim 124, wherein the cells are instilled with a catheter.

D' 126. (New) The method of claim 125, wherein the catheter comprises a balloon means.

127. (New) The method of claim 126, wherein the balloon means comprises two spaced apart inflatable members.

128. (New) The method of claim 127, wherein the balloon means further comprises an instillation port positioned between the inflatable members.

129. (New) The method of claim 126, wherein the balloon means comprises an inflatable member near the distal end of the catheter.

130. (New) The method of claim 129, wherein the balloon means further comprises an instillation port proximal to the inflatable member.

131. (New) The method of claim 122, wherein the cells are instilled surgically.

132. (New) The method of claim 122, wherein the cells are instilled percutaneously.

133. (New) The method of claim 122, wherein the cells are instilled by high pressure instillation.
134. (New) The method of claim 122, wherein the cells are instilled by injection into the patient.
135. (New) The method of claim 134, wherein the injection occurs in a capillary bed.
136. (New) The method of claim 115, wherein the cells are instilled to treat a cardiovascular disease.
137. (New) The method of claim 136, wherein the cardiovascular disease is ischemic cardiomyopathy.
138. (New) The method of claim 115, wherein the cells are instilled into the heart.
139. (New) The method of claim 115, wherein the cells are instilled into the kidney.
140. (New) The method of claim 115, wherein the cells are instilled into the bowel.
141. (New) The method of claim 115, wherein the cells are instilled into the liver.
142. (New) The method of claim 115, wherein the instillation occurs at an angioplasty site following an angioplasty procedure.
-


Applicant wishes to clarify that a mistake in claim numbering within the Preliminary Amendment of December 10, 1999 led to the claims being numbered incorrectly. Within the Office Action of March 29, the Examiner has properly numbered the claims (with the exception that the final claim should be numbered 105 and not 104). In an attempt to clarify the claim numbering situation, Applicant herein cancels all previous claims and represents the claims chosen by the Election herewith as new claims 106-143. These new claims are identical to claims 68-76 (Applicant's numbering) presented in the Preliminary Amendment of December 10, 1999 and claims 77-104 (Applicant's numbering) presented in the Preliminary Amendment of March 24, 2000.

Furthermore, within the Preliminary Amendment of December 10, 2000, it was the intent of the Applicant to cancel all previous claims (see top of page 2 of the Preliminary Amendment). Thus, claims 31-32, as numbered by the Examiner, were not presented for Examination in the present application.

Claims 106-142 are currently pending. Applicant reserves the right to pursue the subject matter of non-elected cancelled claims in a related applications. Applicant respectfully requests an action on the merit of the pending claims. If there are any questions regarding this matter, the Examiner is invited to call the undersigned at (312) 321-4714.

Date: April 30, 2001

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'T. Wrona', is written over a horizontal line.

Thomas J. Wrona
Reg. No. 44,410
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4283